Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Benitec Biopharma (NASDAQ: BNTC) Holds $180M Cash as BB-301 Study Advances

Benitec Biopharma Inc. (NASDAQ: BNTC) had $180.0 million in cash and cash equivalents at June 30, 2026, while its BB-301 program progressed through clinical follow-up, enrollment and regulatory planning.

Vinay Lochav | 15 September 2026

BioMarin (NASDAQ: BMRN) Adds Robert Plenge With $400,000 RSU Grant

BioMarin appointed Robert Plenge to its board and granted him 6,140 restricted stock units valued at $400,000. The award will vest immediately before the company’s next regular annual meeting, while his committee appointment and standard director fees define the stated terms for investors.Key HighlightsRobert …

Vinay Lochav | 15 September 2026

BioMarin Director Awarded 6,140 Shares at $0 (NASDAQ: BMRN)

BIOMARIN PHARMACEUTICAL INC (NASDAQ: BMRN) awarded director Robert M Plenge 6,140 shares at $0 per share. The transaction was recorded on Sep 10, 2026.

Vinay Lochav | 15 September 2026

Caris Life Sciences (NASDAQ: CAI) to Post Investor Presentation Online

Investor Presentation Set for Conference Meetings

Vinay Lochav | 15 September 2026

Portnoy Adam D. Awarded 59,681 DHC Shares

Portnoy Adam D. was awarded 59,681 shares of Diversified Healthcare Trust (NASDAQ: DHC) on 10 September 2026. Following the transaction, the trust’s director held 487,239 shares, while the transaction represented about 12.2% of that holding.

Vinay Lochav | 15 September 2026

Edwards Lifesciences (NYSE: EW) Controller Retains 14,615 Shares After Forfeiture

Edwards Lifesciences Corp (NYSE: EW) recorded a forfeiture of 253 shares by Andrew M. Dahl at $84.37 per share. Dahl is the company’s SVP and Corporate Controller.

Vinay Lochav | 15 September 2026

Why ASTH, VMD, NRC, SRTA and PNTG Are Five Healthcare Services Stocks to Watch in the Nasdaq Composite in September 2026

● Astrana Health reported second-quarterRevenueof $972.5 million, up 49% year over year, and raised full-year 2026 guidance to revenue of $4.1 billion and adjusted EBITDA of $280 million.

Nitish Kishor | 15 September 2026

AXGN, IRWD, TVTX, NRIX and PVLA Could Shape the Biotech and Health Technology Story Across the Nasdaq Composite in September 2026

Biotech and health technology rarely move as a single block, and that is exactly the point. As of mid-September 2026, theNasdaqComposite houses companies at every stage of the healthcare life cycle, from profitable commercial franchises to pre-revenue clinical developers burning cash toward a first …

Nitish Kishor | 15 September 2026

CGON, KTTA, GRAL, ABCL and BLTE Bring Biotech and Health Technology Into Focus for the Nasdaq Composite in September 2026

Biotech rarely moves as a single block, and this quintet proves it. Grouped only by their Nasdaq listing and their place in health innovation, CG Oncology (NASDAQ:CGON), Pasithea Therapeutics (NASDAQ:KTTA), GRAIL (NASDAQ:GRAL), AbCelleraBiologics(NASDAQ:ABCL) and Belite Bio (NASDAQ:BLTE) sit at wildly different points on the …

Nitish Kishor | 15 September 2026

Why ENTX, TWST, JBIO, TLPH and OVID Are Biotech Stocks Worth Watching This Autumn

● Entera Bio closed a BVF Partners-led privatePlacementin July 2026 at $2.04 per share, extending its cash runway into 2030 ahead of a planned Phase 3 start for oral-peptide candidate EB613.

Nitish Kishor | 15 September 2026
Support

Hi! How can we help you today?

Loading…